Head and neck cancer
HN009
RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH HIGH-DOSE CISPLATIN (100 MG/M2) EVERY THREE WEEKS VERSUS RADIATION WITH LOW-DOSE WEEKLY CISPLATIN (40 MG/M2) FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Topic
NRG-HN009
Disease
Head & Neck
Description
To determine whether radiation with low-dose cisplatin weekly is superior in terms of acute toxicity, as measured by the T-scores (TAME method), to radiation with high-dose cisplatin every 3 weeks for patients with locoregionally advanced squamous cell carcinoma of the head and neck
Contact
Physicians
Frank A. Vicini
MD, FACR, FASTRO, FABS
Radiation Oncologist
Farmington Hills (Radiation oncology) +2
Eduardo B. Fernandez
MD, PhD, DABR, FACRO, FASTRO
Radiation Oncologist
Aventura (Radiation oncology) +3
